At the news
? BULLISHIMPACT 7/10 6-K filed Jun 3, 2026 at 08:30 ET
Alpha Tau Medical Ltd. announced a strategic collaboration with Tolmar International Ltd. to develop and commercialize Alpha DaRT therapy for prostate cancer in the U.S. Tolmar will make an initial $15M manufacturing investment and a $20M equity investment at $11.99 per share (25% premium to 30-day VWAP), with up to $161.5M in milestone payments. The deal provides near-term capital and a commercial pathway for a key pipeline asset, but involves significant dilution (1.9% of shares outstanding) and milestone-dependent upside.
- Tolmar receives exclusive U.S. commercialization rights for Alpha DaRT in prostate cancer for 20 years from first commercial sale.
- Tolmar will invest $20M in Alpha Tau at $11.99/share (25% premium to 30-day VWAP), issuing 1,668,057 ordinary shares.
- Tolmar will pay $15M for construction of a new U.S. manufacturing facility.
- Up to $161.5M in clinical, regulatory, and commercial milestone payments for the first prostate cancer indication.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access